Axsome Therapeutics, Inc. (AXSM) vs Kymera Therapeutics, Inc. (KYMR)
A side-by-side comparison of Axsome Therapeutics, Inc. and Kymera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AXSM
Axsome Therapeutics, Inc.
$174.96HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
KYMR
Kymera Therapeutics, Inc.
$104.91HealthcareDelayed quote: Oct 6, 2026, 12:40 PM EDT
Total return — AXSM vs KYMR
growth of $100 · dividends reinvested · last 6yAXSM +124.3% (+14.4%/yr)KYMR +230.3% (+22.0%/yr)KYMR compounded faster over this window
AXSM KYMR
AXSM vs KYMR: by the numbers
- •AXSM is the larger company ($9.00B vs $8.63B market cap).
- •Both run net losses; AXSM's is the smaller (-24.68% vs -285.41% net margin).
Metrics side by side
Valuation
| Metric | AXSM | KYMR |
|---|---|---|
| P/S ratio | 11.59 | 82.20 |
| P/B ratio | 108.08 | 5.72 |
Profitability
| Metric | AXSM | KYMR |
|---|---|---|
| Gross margin | 93.24% | 101.98% |
| Operating margin | -24.28% | -891.33% |
| Net margin | -24.68% | -285.41% |
| ROE | -230.05% | -19.85% |
| ROIC | -50.82% | -22.30% |
Growth (annualized)
| Metric | AXSM | KYMR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 10.22% |
| Total return CAGR (5Y) | 41.40% | 12.31% |
Frequently asked
- How have AXSM and KYMR total returns compared?
- Over the past 5 years, AXSM delivered 41.40% and KYMR delivered 12.31% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Axsome Therapeutics ROEKymera Therapeutics ROEAxsome Therapeutics operating marginKymera Therapeutics operating marginAxsome Therapeutics revenue growthKymera Therapeutics revenue growthAxsome Therapeutics free cash flowKymera Therapeutics free cash flow
Axsome Therapeutics & Kymera Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.